Entera Bio Ltd. (ENTX)

$1.38

+0.05 (+3.76%)
Rating:
Recommendation:
-
Symbol ENTX
Price $1.38
Beta 1.654
Volume Avg. 0.04M
Market Cap 39.758M
Shares () -
52 Week Range 1.31-6.24
1y Target Est -
DCF Unlevered ENTX DCF ->
DCF Levered ENTX LDCF ->
ROE 92.62% Strong Buy
ROA 97.15% Strong Buy
Operating Margin -
Debt / Equity 13.00% Neutral
P/E -
P/B 2 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ENTX news


Mr. Adam Gridley
Healthcare
Biotechnology
NASDAQ Capital Market

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.